MX2010008371A - Inhibidores de catepsina b. - Google Patents

Inhibidores de catepsina b.

Info

Publication number
MX2010008371A
MX2010008371A MX2010008371A MX2010008371A MX2010008371A MX 2010008371 A MX2010008371 A MX 2010008371A MX 2010008371 A MX2010008371 A MX 2010008371A MX 2010008371 A MX2010008371 A MX 2010008371A MX 2010008371 A MX2010008371 A MX 2010008371A
Authority
MX
Mexico
Prior art keywords
fibrosis
hcv
liver
disease
liver fibrosis
Prior art date
Application number
MX2010008371A
Other languages
English (en)
Spanish (es)
Inventor
Leslie Holsinger
Original Assignee
Virobay Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virobay Inc filed Critical Virobay Inc
Publication of MX2010008371A publication Critical patent/MX2010008371A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
MX2010008371A 2008-02-07 2009-02-05 Inhibidores de catepsina b. MX2010008371A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2700708P 2008-02-07 2008-02-07
PCT/US2009/033229 WO2009100225A1 (en) 2008-02-07 2009-02-05 Inhibitors of cathepsin b

Publications (1)

Publication Number Publication Date
MX2010008371A true MX2010008371A (es) 2010-10-04

Family

ID=40939419

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010008371A MX2010008371A (es) 2008-02-07 2009-02-05 Inhibidores de catepsina b.

Country Status (9)

Country Link
US (1) US8211897B2 (https=)
EP (1) EP2237793A4 (https=)
JP (2) JP5718647B2 (https=)
CN (1) CN101969973B (https=)
BR (1) BRPI0907729A2 (https=)
CA (1) CA2713108A1 (https=)
EA (1) EA201001262A1 (https=)
MX (1) MX2010008371A (https=)
WO (1) WO2009100225A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010526834A (ja) 2007-05-10 2010-08-05 インターミューン・インコーポレーテッド Ｃ型肝炎ウイルス複製の新規ペプチド阻害剤
WO2009142842A2 (en) 2008-04-15 2009-11-26 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
AR075584A1 (es) 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
EP2782903B1 (en) 2011-11-25 2016-04-06 F.Hoffmann-La Roche Ag Novel pyrrolidine derivatives as inhibitors of cathepsin
US20140256698A1 (en) * 2013-03-11 2014-09-11 Virobay, Inc. Cathepsin inhibitors
JP7114076B2 (ja) 2015-12-22 2022-08-08 シャイ・セラピューティクス・エルエルシー がん及び炎症性疾患の処置のための化合物
HUE064412T2 (hu) 2016-06-21 2024-03-28 Orion Ophthalmology LLC Heterociklusos prolinamid-származékok
JP7164521B2 (ja) 2016-06-21 2022-11-01 オリオン・オフサルモロジー・エルエルシー 炭素環式プロリンアミド誘導体
JP2019526563A (ja) * 2016-08-23 2019-09-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｈｔｒａ１阻害剤としての新規ジフルオロケタミド誘導体
US10834908B2 (en) * 2017-04-26 2020-11-17 InfiCure Bio AB Model animal for fibrosis
JP7514005B2 (ja) 2017-06-21 2024-07-10 シャイ・セラピューティクス・エルエルシー がん、炎症性疾患、ラソパシー、及び線維性疾患の治療のためのｒａｓスーパーファミリーと相互作用する化合物
US11452709B2 (en) * 2017-07-17 2022-09-27 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for preventing and treating radiation-induced bystander effects caused by radiation or radiotherapy
JP7407461B2 (ja) 2018-12-19 2024-01-04 シャイ・セラピューティクス・エルエルシー がん、炎症性疾患、ｒａｓ病、及び線維性疾患の処置のためのｒａｓスーパーファミリーと相互作用する化合物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2309690A1 (en) * 1997-11-11 1999-05-20 Pfizer Products Inc. Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
US6404397B1 (en) * 1998-08-10 2002-06-11 Raytheon Company Compact all-weather electromagnetic imaging system
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
EP1254901A4 (en) * 2000-01-26 2003-03-05 Ono Pharmaceutical Co 5-CHAIN CYCLIC COMPOUNDS, CONTAINING NITROGEN, AND MEDICINAL PRODUCTS CONTAINING THE SAME AS ACTIVE INGREDIENTS
CA2369970A1 (en) * 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
RS20060197A (sr) 2003-09-22 2008-09-29 Boehringer Ingelheim International Gmbh., Makrociklični peptidi koji su aktivni protiv hepatitisa c virusa
WO2006113942A2 (en) 2005-04-20 2006-10-26 Schering Corporation Method of inhibiting cathepsin activity
WO2006130552A2 (en) 2005-06-02 2006-12-07 Schering Corporation Methods of treating hepatitis c virus
WO2006130554A2 (en) 2005-06-02 2006-12-07 Schering Corporation Methods of treating hepatitis c virus
US20060287248A1 (en) 2005-06-02 2006-12-21 Schering Corporation Asymmetric dosing methods
US7608592B2 (en) * 2005-06-30 2009-10-27 Virobay, Inc. HCV inhibitors
RU2008152171A (ru) * 2006-07-05 2010-08-10 Интермьюн, Инк. (Us) Новые ингибиторы вирусной репликации гепатита с
US20080161254A1 (en) 2007-01-03 2008-07-03 Virobay, Inc. Hcv inhibitors

Also Published As

Publication number Publication date
US8211897B2 (en) 2012-07-03
JP2011511089A (ja) 2011-04-07
EA201001262A1 (ru) 2011-04-29
JP2015051985A (ja) 2015-03-19
CA2713108A1 (en) 2009-08-13
BRPI0907729A2 (pt) 2015-07-14
CN101969973A (zh) 2011-02-09
WO2009100225A1 (en) 2009-08-13
US20090203629A1 (en) 2009-08-13
EP2237793A4 (en) 2013-07-31
EP2237793A1 (en) 2010-10-13
JP5718647B2 (ja) 2015-05-13
CN101969973B (zh) 2015-07-22

Similar Documents

Publication Publication Date Title
MX2010008371A (es) Inhibidores de catepsina b.
JP2015523362A5 (https=)
MX2009003468A (es) Anticuerpo humanizado contra beta amiloide.
TW200603788A (en) Multivalent vla-4 antagonists comprising polymer moieties
IL190084A (en) Amidated pyrimidinyl compounds that inhibit adherence to 4-vla mediated leukocytes
WO2010000372A3 (en) New drug for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases
WO2008060364A3 (en) Humani zed antibody against amyloid beta
UA95267C2 (en) Heteroaryl substituted benzothiazoles
WO2007030375A3 (en) Lysosomal acid lipase therapy for nafld and related diseases
TW200512195A (en) Benzamide 2-hydroxy-3-diaminoalkanes
IL190835A0 (en) Sulfonamide derivatives, their preparation and use
WO2009028457A1 (ja) 非アルコール性脂肪肝炎治療薬
ZA200705018B (en) Malonamide derivatives as inhibitors of gamma-secretase for the treatment of Alzheimer's disease
WO2007067979A3 (en) Targeting vector-phospholipid conjugates
WO2007033080A3 (en) Alzheimer's disease imaging agents
MX2010008535A (es) Forma polimorfa de un derivado de [1,2,4] triazolo [4,3-a] piridina para tratamiento de enfermedades inflamatorias.
WO2011056477A3 (en) Methods for treating inflammation and oxidative stress related diseases
WO2006078576A3 (en) Aminomethyl beta-secretase inhibitors for the treatment of alzheimer's disease
WO2009076388A3 (en) Targeting vector-phospholipid conjugates
WO2005111020A3 (en) Pyrimidine hydantoin analogues which inhibit leukocyte adhesion mediated by vla-4
ATE502031T1 (de) Carbamatverbindungen, die die durch vla-4 vermittelte leukozytenadhäsion inhibieren
IL180681A0 (en) Pyridine derivatives, their preparation and use
WO2009117283A3 (en) Quinolizidinone m1 receptor positive allosteric modulators
EA201390615A1 (ru) Производные дитерпеноидов, обладающие биологическими свойствами
WO2007034329A3 (en) Compounds and methods for treatment of amyloid-beta-peptide related disorders

Legal Events

Date Code Title Description
FG Grant or registration